Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The fecal microbiota RBX2660, live-jslm (RBL; REBYOTA TM), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials (1)
It is a non-randomized clinical phase III trial studying in RBX2660 in 793 enrolled patients with Clostridioides difficile infection (CDI) (recurrent) (1)
Safety
A subgroup analysis was conducted in 74 enrolled participants with [Inflammatory Bowel Disease (IBD)](brain://UUceGF1S-UOZoI1lctf08Q/InflammatoryBowelDi…